400 related articles for article (PubMed ID: 38003674)
21. A novel stemness-hypoxia-related signature for prognostic stratification and immunotherapy response in hepatocellular carcinoma.
Zhang G; Zhang K; Zhao Y; Yang Q; Lv X
BMC Cancer; 2022 Oct; 22(1):1103. PubMed ID: 36307751
[TBL] [Abstract][Full Text] [Related]
22. Global microarray profiling identified
Weng Q; Chen M; Li M; Zheng YF; Shao G; Fan W; Xu XM; Ji J
J Med Genet; 2019 Jan; 56(1):32-38. PubMed ID: 30120213
[TBL] [Abstract][Full Text] [Related]
23. Recent progress in the immunotherapy of hepatocellular carcinoma: Non-coding RNA-based immunotherapy may improve the outcome.
Afra F; Mahboobipour AA; Salehi Farid A; Ala M
Biomed Pharmacother; 2023 Sep; 165():115104. PubMed ID: 37393866
[TBL] [Abstract][Full Text] [Related]
24. A novel immunogenic cell death-related genes signature for predicting prognosis, immune landscape and immunotherapy effect in hepatocellular carcinoma.
Xu G; Jiang Y; Li Y; Ge J; Xu X; Chen D; Wu J
J Cancer Res Clin Oncol; 2023 Dec; 149(18):16261-16277. PubMed ID: 37698679
[TBL] [Abstract][Full Text] [Related]
25. Tumor Immune Microenvironment and Immunosuppressive Therapy in Hepatocellular Carcinoma: A Review.
Oura K; Morishita A; Tani J; Masaki T
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071550
[TBL] [Abstract][Full Text] [Related]
26. A circRNA-miRNA-mRNA network identification for exploring underlying pathogenesis and therapy strategy of hepatocellular carcinoma.
Xiong DD; Dang YW; Lin P; Wen DY; He RQ; Luo DZ; Feng ZB; Chen G
J Transl Med; 2018 Aug; 16(1):220. PubMed ID: 30092792
[TBL] [Abstract][Full Text] [Related]
27. Mechanisms of immune checkpoint inhibitors: insights into the regulation of circular RNAS involved in cancer hallmarks.
Meng L; Wu H; Wu J; Ding P; He J; Sang M; Liu L
Cell Death Dis; 2024 Jan; 15(1):3. PubMed ID: 38177102
[TBL] [Abstract][Full Text] [Related]
28. Cancer cell-derived exosomal circUHRF1 induces natural killer cell exhaustion and may cause resistance to anti-PD1 therapy in hepatocellular carcinoma.
Zhang PF; Gao C; Huang XY; Lu JC; Guo XJ; Shi GM; Cai JB; Ke AW
Mol Cancer; 2020 Jun; 19(1):110. PubMed ID: 32593303
[TBL] [Abstract][Full Text] [Related]
29. Anti-PD-1/PD-L1 Blockade Immunotherapy Employed in Treating Hepatitis B Virus Infection-Related Advanced Hepatocellular Carcinoma: A Literature Review.
Li B; Yan C; Zhu J; Chen X; Fu Q; Zhang H; Tong Z; Liu L; Zheng Y; Zhao P; Jiang W; Fang W
Front Immunol; 2020; 11():1037. PubMed ID: 32547550
[TBL] [Abstract][Full Text] [Related]
30. m6A regulator-mediated methylation modification patterns and tumor microenvironment infiltration characterization in hepatocellular carcinoma.
Huang X; Qiu Z; Li L; Chen B; Huang P
Aging (Albany NY); 2021 Aug; 13(16):20698-20715. PubMed ID: 34461607
[TBL] [Abstract][Full Text] [Related]
31. Identification of LOXL3-associating immune infiltration landscape and prognostic value in hepatocellular carcinoma.
Wang N; Zhou X; Tang F; Wang X; Zhu X
Virchows Arch; 2021 Dec; 479(6):1153-1165. PubMed ID: 34448895
[TBL] [Abstract][Full Text] [Related]
32. Immunomodulatory TGF-β Signaling in Hepatocellular Carcinoma.
Chen J; Gingold JA; Su X
Trends Mol Med; 2019 Nov; 25(11):1010-1023. PubMed ID: 31353124
[TBL] [Abstract][Full Text] [Related]
33. An immune-related biomarker index for predicting the effectiveness of immunotherapy and prognosis in hepatocellular carcinoma.
Wu X; Jin B; Liu X; Mao Y; Wan X; Du S
J Cancer Res Clin Oncol; 2023 Sep; 149(12):10319-10333. PubMed ID: 37273105
[TBL] [Abstract][Full Text] [Related]
34. Progress and prospects of circular RNAs in Hepatocellular carcinoma: Novel insights into their function.
Hu J; Li P; Song Y; Ge YX; Meng XM; Huang C; Li J; Xu T
J Cell Physiol; 2018 Jun; 233(6):4408-4422. PubMed ID: 28833094
[TBL] [Abstract][Full Text] [Related]
35. The Mechanism Underlying the ncRNA Dysregulation Pattern in Hepatocellular Carcinoma and Its Tumor Microenvironment.
Xue C; Gu X; Bao Z; Su Y; Lu J; Li L
Front Immunol; 2022; 13():847728. PubMed ID: 35281015
[TBL] [Abstract][Full Text] [Related]
36. Optimizing radiotherapy with immune checkpoint blockade in hepatocellular carcinoma.
Choi C; Yoo GS; Cho WK; Park HC
World J Gastroenterol; 2019 May; 25(20):2416-2429. PubMed ID: 31171886
[TBL] [Abstract][Full Text] [Related]
37. High-throughput circular RNA sequencing reveals the profiles of circular RNA in non-cirrhotic hepatocellular carcinoma.
Li H; Xu L; Yi P; Li L; Yan T; Xie L; Zhu Z
BMC Cancer; 2022 Aug; 22(1):857. PubMed ID: 35931993
[TBL] [Abstract][Full Text] [Related]
38. Non-coding RNA-associated competitive endogenous RNA regulatory networks: Novel diagnostic and therapeutic opportunities for hepatocellular carcinoma.
Khashkhashi Moghadam S; Bakhshinejad B; Khalafizadeh A; Mahmud Hussen B; Babashah S
J Cell Mol Med; 2022 Jan; 26(2):287-305. PubMed ID: 34907642
[TBL] [Abstract][Full Text] [Related]
39. N6-methyladenosine (m6A) RNA methylation regulator SNRPC is a prognostic biomarker and is correlated with immunotherapy in hepatocellular carcinoma.
Cai J; Zhou M; Xu J
World J Surg Oncol; 2021 Aug; 19(1):241. PubMed ID: 34389000
[TBL] [Abstract][Full Text] [Related]
40. The State of Immunotherapy in Hepatobiliary Cancers.
Ilyas FZ; Beane JD; Pawlik TM
Cells; 2021 Aug; 10(8):. PubMed ID: 34440865
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
